Related Experiment Videos
Fluid retention mediated by renal PPARgamma.
1U545 INSERM Départment d'Athérosclérose Institut Pasteur de Lille and Faculté de pharmacie Université Lille II Lille, France.
Cell Metabolism
|August 16, 2005
Summary
Thiazolidinediones improve glucose control but cause fluid retention. This is because the nuclear receptor PPARgamma plays a key role in how the kidneys handle sodium.
Area of Science:
- Endocrinology
- Nephrology
- Pharmacology
Background:
- Thiazolidinediones are drugs that activate the nuclear receptor PPARgamma.
- These drugs effectively improve glucose homeostasis.
- However, thiazolidinedione treatment is associated with fluid retention and edema.
Purpose of the Study:
- To investigate the role of PPARgamma in renal sodium reabsorption.
- To elucidate the mechanism behind thiazolidinedione-induced plasma volume expansion.
Main Methods:
- Review of recent studies on PPARgamma function in the kidneys.
- Analysis of the link between PPARgamma activation and sodium transport.
Main Results:
- PPARgamma plays a significant role in regulating sodium reabsorption in the kidneys.
- This function of PPARgamma provides a molecular mechanism for the fluid retention observed with thiazolidinedione therapy.
Conclusions:
- PPARgamma activation by thiazolidinediones contributes to increased renal sodium reabsorption.
- Understanding this mechanism may lead to strategies for mitigating side effects of these diabetes medications.